MktsMarkets

Mineralys Therapeutics, Inc.
NASDAQ: MLYSKey statistics
MLYS News
Stories mentioning MLYS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 24,365 | 24,402 | 31,450 | 38,278 | 37,879 | 44,569 | 53,985 | 39,273 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 45,340 | 38,280 | 41,131 | 46,746 | 44,447 | 51,767 | 60,106 | 45,168 |
| Operating Income (Loss) | (45,340) | (38,280) | (41,131) | (46,746) | (44,447) | (51,767) | (60,106) | (45,168) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 5.00 | 1.00 | 4.00 | (2.00) | (3.00) | 12.00 | (10.00) | 2.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (39,339) | (32,234) | (36,932) | (43,274) | (42,211) | (48,946) | (56,342) | (41,014) |
| Earnings Per Share (Basic) | (0.47) | (0.48) | (0.52) | (0.66) | (0.79) | (1.01) | (1.13) | (0.83) |
| Earnings Per Share (Diluted) | (0.47) | (0.48) | (0.52) | (0.66) | (0.79) | (1.01) | (1.13) | (0.83) |
| Weighted Average Shares Outstanding (Basic) | 82,835 | 67,656 | 70,595 | 65,451 | 53,164 | 48,540 | 49,815 | 49,356 |
| Weighted Average Shares Outstanding (Diluted) | 82,835 | 67,656 | 70,595 | 65,451 | 53,164 | 48,540 | 49,815 | 49,356 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About MLYS
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a stock listed on the Nasdaq Stock Market under the ticker symbol MLYS. It last traded at $14.34 (Nov 19, 2026, 1:28 PM ET), up 4.1% on the day. That gives Mineralys Therapeutics a market capitalisation of $1.2B.
Over the past 52 weeks MLYS has traded between $13.72 and $44.99.
For the quarter ended Mar 31, 2026 it reported a net loss of $39.3M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$39.3M |
| Dec 31, 2025 | — | -$32.2M |
| Sep 30, 2025 | — | -$36.9M |
| Jun 30, 2025 | — | -$43.3M |
From Mineralys Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…